The development of alloreactivity following stem cell transplantation (SCT) in HLA matched donorrecipient pairs (DRP) appears to be random. Minor histocompatibility antigens (mHA) 
Introduction
Over the last four decades there have been substantial strides made in the optimizing the clinical outcomes following allogeneic stem cell transplantation (SCT). Nevertheless, outcomes such as relapse and graft versus host disease (GVHD) remain difficult to predict in individuals because of the variability observed in the incidence of alloreactivity following HLA matched SCT using conventional GVHD prophylaxis regimens. [1, 2, 3, 4, 5, 6, 7] To an extent this is also true of HLA mismatched transplantation using novel GVHD prophylaxis regimens. [8, 9] Considering that disease responses in allogeneic SCT are often linked to the development of GVHD, it is important to understand the biological basis of the randomness observed in the incidence of alloreactivity. [10] Relapse and GVHD are a function of donorderived immune reconstitution, which shows many characteristics of a dynamical system, such as logistic growth kinetics and power law distribution of clonal frequencies. [11, 12, 13, 14, 15] This implies that if the quantitative basis of randomness in clinical outcomes can be understood in terms of donor derived immune reconstitution, it will become possible to modify the system to optimize clinical outcomes.
In HLA Matched SCT, recipient antigens, specifically, minor histocompatibility antigens (mHA) are presented on the HLA molecules. These mHA released following conditioning or infection induced-tissue injury are taken up by antigen presenting cells and presented to non-tolerant donor T cells, which in the event of antigen recognition, proliferate and home back to the target tissue initiating a graft vs. host response. Quantifying the mHA disparity in a SCT donor-recipient-pair (DRP) may therefore allow exploration of the origin of the stochastic nature of alloreactivity. It has been shown that both the magnitude and rate of recovery of donor-derived T cells influence the likelihood of relapse, GVHD and survival. [11] This indicates that T cell responses to recipient antigens may be modeled as dynamical systems, with quantitative rules that govern repertoire evolution under normal circumstances and following transplantation. T cell repertoire is exceedingly complex, it is very likely that the antigenic background will be equally as complex. Therefore the antigenic background in a DRP may be similarly described mathematically as a component of this dynamical system. These antigenic differences in a given transplant DRP may be partially determined using whole exome sequencing (WES) of SCT donor and recipient DNA. WES has demonstrated that there is a large library of non-synonymous single nucleotide polymorphisms (nsSNP), and an equally large array of nsSNP-derived-peptides which would have different amino acid sequences in each DRP. [16, 17] Of these nsSNPs, those present in the recipient but absent in the donor will in theory, yield an array of immunogenic recipient peptides which may trigger donor T cell activation and proliferation, in other words, an array of mHA bound to the 'matched' HLA in the DRP. In aggregate these polymorphisms constitute an alloreactivity potential between the specific donors and recipients. In studies done to date, large magnitude of this alloreactivity potential has been observed in all the HLA matched DRP examined. When a dynamical T cell response to this mHA array is calculated marked variation in the simulated T cell response is observed, suggesting that the number and the HLA binding affinity of the mHA may determine that likelihood of alloreactivity. [18] Similar observation reporting association of polymorphisms in the peptide regions of HLA class I molecules support the premise outlined above. [19] Nevertheless, alloreactivity is a complex clinical state, where patients may have variable manifestations of GVHD impacting different organ systems to varying extent. In this paper the impact of tissue-specificexpression of the proteins that the mHA are derived from in different individuals is examined to measure its variability between unique transplant DRP. This is done using a T cell vector-mHA operator system previously developed [18] with a uniform set of conditions employed to simulate a hypothetical CD8+ T cell response to the in silico derived mHA-HLA class I array in 77 HLA matched SCT DRP. Table 1 ). HLA matching had been performed using high resolution typing for the unrelated donor SCT recipients; and intermediate resolution typing for class I, and high resolution typing for class II antigens for related donor recipients. A variety of different conditioning and GVHD prophylaxis regimens were used in the patients. HLA class I typing information for the donor and recipient was acquired from the clinical data base.
Methods.

Patients
Whole Exome Sequencing
Nextera Rapid Capture Expanded Exome Kit was used to extract exomic regions from the DNA samples, which were then multiplexed and sequenced on an Illumina HiSeq 2500 to achieve an average coverage of ~90X per sample. 2X100 bp sequencing reads were then aligned to the human reference genome using BWA aligner. Duplicate read alignments were detected and removed using Picard tools. Single nucleotide polymorphisms (SNPs) in both the donor and recipients' exomes were determined using GATK HaplotypeCaller walker. GATK best practices were then implemented to filter and recalibrate the SNPs; and store them in variant call file (VCF) format. To identify SNPs unique to the recipient and absent in the donor the results from the GATK pipeline in VCF format were then parsed through the inhouse TraCS (Transplant pair Comparison System) set of perl scripts. TraCS traverses through the genotypes of the called SNPs, systematically excluding identical SNPs or editing them to align with the graft-versus-host (GVH) direction thereby generating a new VCF with SNPs for a particular DRP in the GVH direction (SNP present in the recipient, absent in the donor).
The SNPs in this VCF are then annotated either as synonymous or non-synonymous using Annovar. The corresponding amino acid polymorphisms along with flanking regions of each protein are then extracted using Annovar to build peptide libraries of 17-mers for each DRP, with the SNP encoded AA occupying the central position. This library is further expanded by sliding a 9-mer window over each 17-mer such that the polymorphic amino-acid position changes in each 9-mer. The HLA class I binding affinity and IC50 values, which quantify the interactions between all these 9-mers for each DRP and all six HLA class I donor molecules (HLA-A, B and C), NetHMCpan version 2.8 was run iteratively in parallel mode on a linux cluster using custom python scripts. Parsing the NetMHCPan output, unique peptide-HLA combinations present in the recipient but not in the donor, i.e., possessing a GVHD vector, were identified and organized in order of declining mHA-HLA affinity. IC50 (nM) indicated the amount of peptide required to displace 50% of intended or standard peptides specific to a given HLA. Binding affinity is inversely related to IC50, such that, smaller the IC50 value, the stronger is the affinity. The variant alloreactive peptides with a cutoff value of IC50 ≤500 are included in the analyses presented here.
The Genotype-Tissue Expression (GTEx) portal V6 has publicly available expression level information (Reads/kilobase of transcripts/million mapped reads, RPKM values; http://www.gtexportal.org/home/) for a variety of human tissues over a large number of genes. As we know the genes from where the peptides in our DRP peptide library are originating from, we are able to parse in the RPKM values from the GTEx portal for that gene across the whole array of tissues of interest, namely, skin, lung, salivary gland, esophagus, small intestine, stomach, colon and liver. In the DRP where a male recipient had been transplanted from a female donor (n=17), full length available sequences of all proteins encoded by the Y chromosome were curated from NCBI and other resources (see supplementary material). These sequences were then computationally split into 9-mer peptides and their respective binding affinities and IC50 values for the relevant donor HLA antigens were determined in silico using the NetMHCpan software as described earlier. These peptides were then appended to the corresponding DRPs peptide library for all subsequent analyses.
Computational Methods: Dynamical System Modeling Of T Cell Response To Putative mHA
It was postulated that the immune effectors and their antigenic targets constitute a dynamical system, i.e. an iterating physical system, where the variable being studied evolves over time, and the state of any variable at any given time (t), is predicated on all the preceding states of the systems. A system demonstrating logistic growth of immune effectors may be described by the general equation
Here, dN/dt is the instantaneous rate of change of the cell population at time t, when the population N t has an intrinsic growth rate, r and a maximum size, K. This logistic dynamical system constitutes a system of repeated calculations, where the output of the equation for each iteration gives the population N t , as a function of time, and becomes the input variable (argument) for the next calculation N t+1 . This system behaves in a non-linear fashion, demonstrating sigmoid population growth constrained by feedback. [18, 20, 21] If SCT is considered as a system of interacting donor T cell clones and recipient antigens, immune reconstitution following SCT may be modeled mathematically. Each T cell clone responding to its target antigen will proliferate, conforming to the iterating logistic equation of the general form The alloreactivity matrix modifies the donor T cell clonal vector infused with an allotransplant, mapping it to the recipient T cell vector, as the T cell clones with unique TCR encounter the corresponding mHA-HLA complexes they proliferate conforming to the logistic equation [1] . In the logistic equation K for each T cell clone will be proportional to the approximate binding affinity (1 50) of the corresponding mHA-HLA complex ( !/!"!" ). The parameter r is a function of the binding affinity (by increasing the TCRmHA-HLA interaction time) and the intrinsic T cell proliferation capacity. Equation 1 must therefore be modified for unique TC clone TCx, responding to mHAx-HLA, as follows:
This general equation gives instantaneous T cell counts in response to antigens presented, regardless of tissue distribution. In the alloreactivity, vector-operator identity matrix, the values 1 or 0 in each cell are multiplied by the product of equation 3 for each T cell clone. This is depicted in Matrix II.
Matrix II. Matrix illustrating a single iteration of the alloreactivity operator !"# on T cell vector !!" .
Each cell in the matrix calculates the value of TC x in response to mHA x -HLA, final repertoire is determined by solving the matrix.
HLA mHA x HLA
The T cell response to each mHA-HLA complex is determined over time, t, by iterating the system of matrix-equations. In this alloreactivity matrix, the IC50 of all the alloreactive peptides with a GVH direction (present in recipient, but absent in donor) constitutes the operator; the sum of n T cell clones 
Competition between T Cell Clonal Populations
Each of the T cell clones is behaving like a unique population, therefore competition with other T cell clones in the set of all T cell clones must be accounted for in the logistic equation to determine the magnitude of the unique clonal frequencies as the model iterates simulating T cell clonal growth over time. This may be done using the Lotka-Volterra model for competing populations, which accounts for the impact of population growth of multiple coexisting populations [18, 24, 25] . This is accomplished by To account for n competing T cell populations, equation 3 will be modified as follows
Where for the T cell clone x, N t depends on the sum of the n T cell clonal frequencies at the previous iteration, with the α of each T cell clone i, with respect to the T cell clone x, modifying the effect of the frequency of the ith clone on TCx. By contrast, the parameter r can have either positive or negative values depending on whether the ambient cytokine milieu, either stimulates (-r) or suppresses (+r)
growth.
The direction of the T cell clones will be determined by antigen specificity, i.e. whether their TCR recognize the recipient's mHA-HLA (are alloreactive) or not (are tolerant), such as pathogen directed T cell clones. For example, a tolerant, non-autoreactive set of T cell clones (donor vector, !"# ) may be transformed to a predominantly alloreactive set of T cell clones ( !!" ), after interacting with the mHA-HLA complex, alloreactivity operator encountered in the recipient ( !"# ).
Accounting for tissue expression of proteins
The peptides discussed in the afore mentioned derivation are generated from proteins expressed in target tissues, as such the level of protein expression will determine the magnitude of the peptide specific T cell response. The higher the protein expression, the more peptide molecules and the greater the HLA presentation with an ability to stimulate a larger T cell response (clonal frequency). Therefore 
In equation 3.2, the tissue expression of the protein from which the target peptide, mHAx is derived is incorporated as a K multiplier when calculating a tissue-specific T cell response. Thus tissue-specific alloreactivity potentials may be simulated for each of the relevant GVHD target tissues, by substituting equation 3.2 into Matrix II.
In applying this model to exome sequence derived, alloreactive-peptide-HLA binding patient data an IC50 cutoff value of ≤500 nM, and an RPKM value of ≥1 were chosen to study the differences between 
Results.
Exome sequencing
Cryopreserved DNA samples from 78 donors and recipients of allogeneic SCT were sequenced, demographic details of the patients are given in supplementary Fig 1) .
In silico derivation of mHA-HLA complexes from exome variation
The nsSNP GVH data arrays then served as the basis to computationally determine peptide sequences. For 
Simulating recipient tissue specific donor T cell responses
Following determination of the mHA with various binding affinity distributions, the T cell responses to these antigens were simulated using the T cell vector-alloreactivity operator model [Equations 2 & 3.2].
The underlying conditions used in these calculations were as follows: for each mHA there was a single T cell present at the first iteration, i.e. N t = 1 at t = 1. The K in equation 3.2 was set at 1000,000 cells (note:
this value substitutes for organ mass, lympho-vascular supply etc. without accounting for differences between organs), and r was set at 1. give the simulated alloreactive T cell count for each organ in each individual. The average value for each organ at steady state (average of the iteration # 401-500) was determined and is shown for each patient ( Figure 3A ) and depicts the magnitude of organ-specific alloreactive T cell response that may be seen in different DRP, accounting for their HLA types and exome sequence variation. The simulated organspecific T cell counts responding to the alloreactivity operator demonstrate marked variability in both HLA matched related and unrelated donors, both between different DRP ( Figure 3B ) as well as within DRP ( Figure 3C ). This is true for individual organ simulations, as well as the sum of these simulations ( Figure 3D ), which reflects the variation in the organ specific T cell responses.
When the sum of all organ specific T cell clones (Σ TC) was examined in different donor types, no significant differences were observed in any of the categories examined This corroborates well with the relatively weak effect of these biological differences in the development of GVHD in the setting of HLA matching. [26, 27] However the small sample size and heterogeneity of our group in terms of conditioning and GVHD prophylaxis may also contribute to the variability observed in clinical outcomes.
Clinical association of tissue-specific alloreactivity potential
The simulated T cell counts are summarized in Supplementary Table 3 , where for every organ (and overall) the mean simulated T cell counts were larger in patients who eventually developed any form of GVHD, than they were in patients who did not develop GVHD, though none of these differences were significant. As can be seen in Supplementary Table 4 , that while none of the organ-specific simulated T cell counts were associated with GVHD (all p-values between 0.05 and 0.15), the variability (standard deviation) among organ-specific T cell estimates in individuals is significantly associated (HR = 1.08, 95%
CI: 1.01, 1.15, p = 0.0275) with GVHD, as was the maximum organ-specific T cell estimate (HR = 1.01, 95% CI: 1.00, 1.02, p-value = 0.0462) and the range between the maximum and minimum organ-specific t-cell counts (HR = 1.02, 95% CI: 1.00, 1.05, p-value = 0.0276). These results imply that increased variability of T cell counts among organs are associated with a minimal increase in the risk of GVHD.
Similar analyses for survival, relapse and relapse-free survival were not significant for any of the organspecific T cell counts or the variability measures (all p-values > 0.5). While these are weak associations at best, it is noteworthy that despite an estimated, uniform set of constants used in the model for all DRP, heterogeneously treated group of patients, overall there was a trend for higher organ specific T cell counts in patients with GVHD compared to those with none.
Cox proportional hazards models for acute and chronic GVHD are presented in Supplementary Table 5, and demonstrated no significant associations between expected t-cell counts and variability measures with acute GVHD (all p-values > 0.05). For chronic GVHD, only the expected T cell counts from the liver were significantly associated, with a slight positive relationship (HR = 1.01, 95% CI: 1.00, 1.03, p-value = 0.0411). The standard deviation among organ-specific t-cell estimates is significantly (p = 0.0404) and positively associated (HR = 1.08, 95% CI: 1.01, 1.16) with GVHD, as was the range between the maximum and minimum organ-specific T cell counts (HR = 1.03, 95% CI: 1.01, 1.05, p-value = 0.0266). These results imply that increased variability of t-cell counts among organs are associated with slight increases in the risk of chronic GVHD.
There were no associations between organ-specific expected T cell counts and the organ-specific occurrence of acute GVHD (all p-values > 0.5). Only expected T cell counts in salivary glands was significantly and positively associated with oral chronic GVHD (HR = 1.02, 95% CI: 1.01, 1.04, p = 0.0131);
all other organ-specific expected t-cell counts were not associated with organ-specific chronic GVHD (pvalues > 0.09).
Discussion.
Alloreactivity following SCT is a complex disorder dependent on a number of factors such as degree of HLA matching, [28, 29, 30] intensity of immunosuppression [31, 32, 33] and the graft source/T cell composition of the graft. [34, 35] However, even within uniformly HLA matched and immunosuppressed patients with similar disease biology, outcomes remain variable and subject to laws of probability. In this paper the magnitude of difference in putative alloantigen presentation between SCT DRP is explored, considerations that needs to be factored in. Logic would dictate that when proteins are cleaved, there will be a host of peptides generated for antigen presentation, both alloreactive, such as the ones reported here, as well as non-alloreactive peptides which will also bind HLA with varying levels of affinity, as the alloreactive peptides do. Furthermore these peptides will likely be far more numerous than the alloreactive ones, and may constitute a significant competitive barrier to the presentation of alloreactive peptides. This may be modeled numerically using the notion of combinatorial probability. of APC growth and decline on T cell clonal proliferation is given by the expression,
This variable is at its highest value, 2, in the beginning of the reaction (N t APC /K APC approaches 0) but as the reaction proceeds over time t, it approaches 1, as N t APC approaches K APC . Here 1 represents the binary (0/1) condition of T cell clone specificity for target mHA in M APO , in real world terms the steady state capability of the T cell to proliferate when encountering the relevant antigen. Assuming that an independent !"# exists for each antigen in the M APO , the effect of APC growth and subsequent mHA presentation may be obtained by the dot product of the two vectors, !"# and !"# . In other words, multiplying each iteration of the T cell vector with each iteration of this APC vector (the operation of multiplying 2 column matrices), transforms the donor T cell vector,
This equation implies that in the beginning of an inflammatory response there is a positive feedback response from proliferating APC, which amplifies the T cell response !"# ′; eventually both decay to a steady state level. The angle θ between the two vectors is 0 ° (cos 0 = 1) because they have the same direction, in other words the TCR recognize the mHA-HLA complex being presented by the APC. This effect of !"# on !"# can be applied to the entire T cell repertoire and is shown in Figure 4A for a single T cell clone and may be generalized to the whole repertoire ( Figure 4B ). As can be seen these graphs recapitulate the T cell response amplification commonly observed in response to antigen stimulation, [40, 41, 42] and can be depicted in the model illustrated in Figure 4C . In practice, this interaction depending on the presence or absence of inflammation in the tissues being studied, will significantly modify the alloreactivity operator and lead to variability in T cell proliferation observed. The weak associations of the T cell simulations with the clinical findings reported in this paper, may therefore be explained by absence of information regarding the overall inflammatory state in each DRP.
This can certainly be modeled in the future iterations of such work.
Another source of clinical variability that is not accounted for in this model is the make up of the graft represents the proliferative effect of the cytokine milieu. In this instance the more negative its value (induced by pro-inflammatory cytokines), the larger the growth promoting effect, and the less negative or positive the value (anti-inflammatory cytokine effect) the more growth will be impeded or stopped, as can be seen in Figure 5 , where a change in the magnitude of r produces dramatic decline in the T cell HLA type and alloreactivity potential determined by whole exome sequencing. A donor with optimal alloreactivity potential will be identified and a GVHD prophylaxis regimen of optimal intensity utilized to achieve maximal likelihood of good clinical outcome. In so doing, dynamical systems understanding of alloimmune T cell responses will attenuate the unpredictability that the current largely probability based models of outcomes prediction expose patients to. The dynamical systems analysis of antigenic variation also explains the randomness at hand in human immune response to disease, either infectious or neoplastic. This understanding has the potential to impact areas of investigation beyond transplant alloreactivity, potentially influencing cancer immunotherapy, autoimmune disease and infectious disease. Randomness within the dynamical system will remain a problem for the foreseeable future, but a model such as this is a step towards gaining a quantitative understanding of complex immune responses.
In conclusion this model partially explains why immune responses are seemingly random and difficult to accurately predict, akin to the quantum uncertainty principle, you can accurately measure either a particle's position or its velocity, never both. Similarly, given the complexity at hand in immune responses, we will not be able to precisely quantify the likelihood of alloreactivity, but with a quantitative understanding give a more accurate estimate of the probability distribution.
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